Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $516 | In Stock | |
10 mg | $828 | In Stock | |
25 mg | $1,230 | In Stock | |
50 mg | $1,650 | In Stock |
Description | Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection. |
In vitro | Vilobelimab selectively neutralizes C5a in a dose-dependent manner without preventing the formation of membrane-attacking complexes and has not raised significant safety concerns in certain clinical studies in patients with severe sepsis and septic shock. [1] |
Alias | IFX-1, IFX1, CaCP-29, CaCP29 |
Cas No. | 2250440-41-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.